StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

Research analysts at StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a research note on Tuesday, December 10th.

Aptose Biosciences Price Performance

Shares of APTO stock opened at $0.23 on Wednesday. Aptose Biosciences has a 12-month low of $0.13 and a 12-month high of $2.60. The firm has a market capitalization of $13.67 million, a price-to-earnings ratio of -0.08 and a beta of 0.87. The business has a 50 day simple moving average of $0.26 and a 200 day simple moving average of $0.42.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp increased its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.